Consensus Zai Lab Limited Börse Stuttgart

Stocks

1ZL

US98887Q1040

Pharmaceuticals

Market Closed - Börse Stuttgart 05:55:42 19/09/26 am AEST			5-day change	1st Jan Change
22.20 ^EUR	-0.89%		+8.74%	+51.35%

05/09	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading	MT
03/09	Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT

99b65f9de.SOdhf6IZo4B_3K9qo_IKuoNlXR5QvyFPRVGkL3O7j_4.AYsbLu0vxvIvis4sxaFw_84OAlZo-04oBxyTWzDW9qkfrRkH-G3ktQeO_g~7d00259a8a0f862cff34cbf4fead802a

Analysts' recommendations: Zai Lab Limited

08/01	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
05/11	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
05/11	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
13/03/25	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
04/03/25	BofA Securities Downgrades Zai Lab to Neutral	MT
13/07/24	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
15/12/23	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
27/10/23	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
27/10/23	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
10/08/23	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
12/06/23	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
11/05/23	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
17/03/23	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
19/11/22	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
12/11/22	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
09/08/22	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
26/05/22	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
12/05/22	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
12/05/22	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
07/05/22	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
22/04/22	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
05/04/22	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
03/03/22	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
03/03/22	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
04/12/21	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+7.58%
	MODERNA, INC.					-24.37%
	CSL LIMITED					+0.05%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.94%
	UCB					+36.63%
	BIOGEN INC.					+8.73%
	INCYTE CORPORATION					+0.09%
	INNOVENT BIOLOGICS, INC.					+34.19%
	SWEDISH ORPHAN BIOVITRUM AB					+12.36%
	Average					+12.91%
	Weighted average by Cap.					+10.04%